Compare Las Vegas Sands Corp. (LVS) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Roivant Sciences Ltd. Common Shares — how do they compare? Las Vegas Sands Corp. trades at $36.2 (market cap $23.38B), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Las Vegas Sands Corp. and Roivant Sciences Ltd. Common Shares are close in size by market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| LVS | ROIV | |
|---|---|---|
Market Cap | $23.38B | $24.72B |
Volume | 6,994,661 | 6,279,442 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $41.81 |
52-Week Low | $35.81 | $16.04 |
Typical Hold Time | 72 Days | 1 Days |
Enterprise Value | $35.27B | $20.99B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.17, up 1.01% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 12.59% net margin and 134.29% ROE, supported by $13.02B in 2025 revenue. Analysts are bullish with a $59.78 consensus target, but the stock faces headwinds from high debt levels and a recent Q2 2026 earnings miss.
The outlook for LVS is mixed; solid fundamentals and analyst support suggest upside, but technical weakness and leverage risks warrant caution. Investment opportunity lies in valuation discount versus peers, while risks include debt servicing and Macao regulatory exposure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
